Last reviewed · How we verify

NCT05161065

Comparison of QT Interval Readings Between Smartwatch Combined With Cardiologs Artificial Intelligence and 12-lead ECG

Completed Last updated 3 October 2023
What this trial tests

trial testing Cardiologs in Atrial Fibrillation in 50 participants. Completed in 28 February 2023.

Timeline
12 February 2022
Primary endpoint
28 February 2023
28 February 2023

Quick facts

Lead sponsorCardiologs Technologies
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date12 February 2022
Primary completion28 February 2023
Estimated completion28 February 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cardiologs Technologies

Who can join

22 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The WatchQT study will compare the performance of a smartwatch combined with Cardiologs ECG AI Analysis system in monitoring corrected QT (QTc) intervals with that measured on a manually read 12-lead ECG in subjects with Normal Sinus Rhythm (NSR) during antiarrhythmic drug (AAD) initiation and follow-up at the hospital.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cardiologs

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Cardiologs Technologies trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05161065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing